Under the Paperwork Reduction Act of 1995, no persons are required to re-

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

| Application Number | | 10774105 | | |
|------------------------|---------|------------------|--|--|
| Filing Date | | 2006-02-04 | | |
| First Named Inventor | DiMauro | | | |
| Art Unit | | 3761 | | |
| Examiner Name | Steph | nens, Jacqueline | | |
| Attorney Docket Number | | DEP5229USNP | | |

| | U.S.PATENTS | | | | | | |
|----------------------|-------------|-------------------------|---------------------------|-----------------|---|--------|---|
| Examiner Initial* | Cite No | Patent Number | Kind Code ¹ | Issue Date | Name of Patentee or Applicant of cited Document | Releva | Columns,Lines where nt Passages or Relevan s Appear |
| | 1 | 6503507 | | 2003-01-07 | Allen | | |
| | 2 | 6527759 | | 2003-03-04 | Tachibana | | |
| | 3 | 6592888 | | 2003-07-15 | Jensen | | |
| | 4 | 6605751 | | 2003-08-12 | Gibbins | | |
| | 5 | 4861484 | | 1989-08-29 | Lichtin | | |
| | 6 | 6572586 | | 2003-06-03 | Animas | | |
| | 7 | 5891082 | | 1999-04-06 | Leone | | |
| lf you wis | h to ac | dd additional U.S. Pate | nt citatio | n information p | lease click the Add button. | | Add |
| | | | U.S.P | ATENT APPL | ICATION PUBLICATIONS | | Remove |

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

| Application Number | | 10774105 | | |
|----------------------|-------|-------------------|--|--|
| Filing Date | | 2006-02-04 | | |
| First Named Inventor | DiMa | DiMauro | | |
| Art Unit | | 3761 | | |
| Examiner Name | Steph | ohens, Jacqueline | | |
| Attorney Docket Numb | er | DEP5229USNP | | |

| Examiner Initial* | Cite No | Publication Number | Kind Code ¹ | Publica Date | ition | Name of Patentee or Applicant | | Pages,Columns,Lines where Relevant Passages or Releva Figures Appear | | | |
|--|---|---|------------------------------|-----------------|---------------------------|-------------------------------|---|--|--------|----------------------|----|
| | 1 | 20030125679 | | 2003-07 | -03 | Kubota | | | | | |
| | 2 | 20030204229 | | 2005-11 | I- 2 2 | Stokes | | | | | |
| If you wish to add additional U.S. Published Application citation information please click the Add button. Add | | | | | | | | | | | |
| | | | | FOREIG | 3N PAT | TENT DOCUM | ENTS | | Remove | | |
| Examiner Initial* | Cite No | Foreign Document Number ³ | Country Code ² | | Kind Code ⁴ | | Name of Patente Applicant of cited Document | licant of cited Where Relevant | | evant or Relevant | т |
| | 1 | | | | | | | | | | |
| If you wis | h to a | dd additional Foreign Pa | atent Do | cument | citation | information pl | ease click the Add | button | = | | |
| | | | NON | I-PATE | NT LITE | RATURE DO | CUMENTS | | Remove | | |
| Examiner Initials* | Cite No | Include name of the au (book, magazine, journ publisher, city and/or of | nal, seri | al, symp | osium, | catalog, etc), o | | | | | Тŝ |
| | 1 | TRAMPUZ, Molecular and antibiotilin approaches to proathetic joint infection, Clin Orthop., 2003, pp. 69-88. Vol. 414 | | | | | | | | | |
| | 2 SHANBHAG, Decreased neutrophil respiratory burst on exposure to cobalt-chrome alloy and polystyrene in vitro, J Borned Mar. Res., 1992, pp 185-95, Vol 26. | | | | | | | | | | |
| | 3 OHKO, Self-sterilizing and self-desiring of silicone calibeters coaled with Ti62 photocatalyst thin films - A preclinical work, J Bio Med. Mat. Res., 2001, pp 97-101 Vol. 58 | | | | | | | | | | |

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

| Application Number | | 10774105 | |
|------------------------|----------------------|--------------|--|
| Filing Date | | 2006-02-04 | |
| First Named Inventor | DiMa | uro | |
| Art Unit | | 3761 | |
| Examiner Name | Stephens, Jacqueline | | |
| Attorney Docket Number | | DEP5229LISNP | |

| 4 | TREPANIER, Effect of modification of oxide layer on NTI stent corrosion resistance, J. Biomed. Mat. Res., 1998, pp. 433-440, Vol. 43 | |
|----|--|--|
| 5 | KAPLAN, Biomaterial-induced alterations of neutrophil superoxide production, J. Biomed. Mat. Res., 1992, pp 1039-51, Vol 26 | |
| 6 | WOLFRUM, Photocatalytic oxidation of bacteria, bacterial and fungal spores, and model biofilm components to carbon dioxide on titansu, dioxide-coated surfaces, ES&T, 2002, pp 3412-19, Vol. 36. | |
| 7 | AKIN, Preparation and analysis of macroporous TiO2 films on Ti surfoes for bone-fissue implants, J. Biomed. Mat. Res., 2001, pp. 598-596, Vol. 57 | |
| 8 | RAMIRES, The influence of titania/hydroxyapatitic composite coatings on in vitro esteroblasts behavior, Biomaterials, June 2001, pp. 1467-74, Vol. 22(12) | |
| 9 | ANPO, Utilization of Ti02 photocatelysts in green chemistry, Pure Appl. Chem., 2000, pp 1265-70, Vol. 72(7) | |
| 10 | YIN, Preparation of nitrogen-dopes fituria with high visible light induced photocatalytic activity by mechanochemical reaction of fituria and hexamethylenetetramine, Mater. Chem., 2003, pp 2996-3001, Vol 31(12) | |
| 11 | SHAH, Study of Nd3+, Pd2+, Pl4+ and Fe3+ depart effect on photoreactivity of Ti02 nanoparticles, PNAS, April 30, 2002, pp 6482-6486, Vol. 99(S2) | |
| 12 | STUTZMAN, CaN-based heterostructures for sensor applications, Diamond and Related Materials, 2002, pp 886-891, Vol. 11 | |
| 13 | WAINRIGHT, Photodynamic antimicrobial chemotherapy PACT, J Antimicrobial Chemotherapy, 1999, pp. 13-28, Vol. 42 | |
| 14 | ZEINA, Killing of cutaneous microbial species by photodynamic therapy, Br. J. Dermatol., 2001, pp. 274-278, Vol. 144 (2) | |

| 15 | ZEINA, Cytotoxic effects of antimics 568-73, Vol. 146 | robial photodynamic therapy on ke | ratinocytes in vitro, B. J. Dermatol 2002, pp | |
|----|--|-----------------------------------|---|--|

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Tack Kinz Code of USPTO Potent Documents at time USETO_COLY or MPEP 901.04. * Enter of this that issued the document, by the bro-letter cole (MPC)
Standard \$13.3.* **Engineers pageted counters, the octobact or the year of the register or temperature preced the serial runber of the patent document.
Indirect document by the appropriate symbols as enclosed on the document under WIPO Standard \$11.0 if possible. **Applicant is to place a check mark here it Engine Imagingues translation is attacked.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

| Application Number | | 10774105 | | |
|----------------------|-------|------------------|--|--|
| Filing Date | | 2006-02-04 | | |
| First Named Inventor | DiMa | uro | | |
| Art Unit | | 3761 | | |
| Examiner Name | Stept | nens, Jacqueline | | |
| Attorney Docket Numb | ec | DEP5229USNP | | |

CERTIFICATION STATEMENT

| Please see 37 | CFR 1.97 | and 1.98 to | make the | appropriate | selection(s | :(: |
|---------------|----------|-------------|----------|-------------|-------------|-----|
|---------------|----------|-------------|----------|-------------|-------------|-----|

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(eV1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(e).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- _ ...

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

| Signature | /Eugene L. Szczecina, Jr./ | Date (YYYY-MM-DD) | 2007-01-17 |
|------------|----------------------------|---------------------|------------|
| Name/Print | Eugene L. Szczecina. Jr. | Registration Number | 35,029 |

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1449, Alexandriv, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandriva, V.S. 2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.